

02-11-05

DFW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Dean L. Engelhardt et al.

Serial No. 10/718,391

Filed: November 19, 2003

Title: **IN VITRO PROCESSES FOR PRODUCING  
MULTIPLE COPIES OF PRIMER SEQUENCE-  
FREE SPECIFIC NUCLEIC ACID**

Group Art Unit: Not Yet Known

Examiner: Not Yet Known

527 Madison Avenue, 9th Floor  
New York, New York 10022  
February 10, 2005


**FILED BY EXPRESS MAIL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
ATTN: Mail Stop SEQUENCE

**REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE  
AND/OR AMINO ACID SEQUENCE DISCLOSURES - FILING DATE GRANTED**

Dear Sirs:

This reply is directed to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No.	<u>EV531083499US</u>
Deposit Date	<u>February 10, 2005</u>
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.	
 Natalie Bogdanos Reg. No. 51,480	<u>2/10/05</u> Date

Enz-52(C2)

Dean L. Engelhardt, et al.

Serial No. 10/718,391

Filed: November 19, 2003

Page 2 (Reply to Notice To Comply With Requirements For Patent  
Applications Containing Nucleotide Sequence And/or Amino  
Acid Sequence Disclosures – Filing Date Granted) – February 10, 2005)

Disclosures – Filing Date Granted (hereinafter “the Notice”) that was mailed on August 10, 2004 in connection with this U.S. patent application, Serial No. 10/713,391 (hereinafter “the ‘391 application”).

In response to the Notice, Applicants, through their attorney, submit the following documents and items:

1. a copy of the Notice, attached herein as Exhibit 1;
2. a Request For An Extension Of Time (Four Months) Under 37 C.F.R. §1.136(a), attached herein as Exhibit 2;
3. an Amendment, attached herein as Exhibit 3, and its attachment identified as Exhibit A, consisting of an initial paper copy of the Sequence Listing;
4. an initial computer readable form (CFR) copy of the Sequence Listing, attached herein as Exhibit 4; and
5. a Request To Correct Filing Receipt, attached herein as Exhibit 5, and its attachment identified as Exhibit A.

In connection with the Sequence Listing submitted concurrently herewith, Applicants, through their attorney, state that: a) the submission, filed herewith in accordance with 37 CFR § 1.821(g), does not include new matter; and b) in accordance with 37 CFR §1.821( c), (e) and (f), the Sequence Listing content of the paper copy (Exhibit A to Exhibit 3) and the computer readable copy of the Sequence Listing (Exhibit 4), are the same.

**ENZ-52(C2)**

Dea<sup>n</sup> L. Engelhardt, et al.

Serial No. 10/718,391

Filed: November 19, 2003


Page 3 (Reply to Notice To Comply With Requirements For Patent  
Applications Containing Nucleotide Sequence And/or Amino  
Acid Sequence Disclosures – Filing Date Granted) – February 10, 2005)

A response to this Notice was due on October 10, 2004. In accordance with Applicants' request for a four-month extension of time, a response is due on February 10, 2005. As such, this reply is being timely filed.

No fee is believed due in connection with this Reply or the documents and items submitted herewith other than the fee that is due in connection with the aforementioned Request For An Extension of Time (Four Months) Under 37 C.F.R. §1.136(a). If any fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Reply, the undersigned may be contacted by telephone at (212) 583-0100 during business hours.

Respectfully submitted,



Natalie Bogdanos  
Registration No. 51,480  
Attorney for Applicants

ENZO LIFE SCIENCES, INC.  
f/k/a Enzo Diagnostics, Inc.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9<sup>th</sup> Fl.)  
New York, New York 10022  
Telephone: (212) 583-0100; Fax: (212) 583-0150

LC/USProsecution/Enz-52(C2).ReplyToNtOfMissingPts.Sequences.021005

**ENZ-52(C2)**



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/718,391	11/19/2003	Dean L. Engelhardt	Enz-52(C2)

Ronald C. Fedus, Esq.  
 Enzo Life Sciences, Inc.  
 c/o Enzo Biochem, Inc.  
 527 Madison Avenue (9th Floor)  
 New York, NY 10022




CONFIRMATION NO. 9721

## FORMALITIES LETTER



\*OC000000013500216\*

Date Mailed: 08/10/2004



## NOTICE TO FILE CORRECTED APPLICATION PAPERS

*Filing Date Granted*

An application number and filing date have been accorded to this application. The application is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given TWO MONTHS from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The required item(s) identified below must be timely submitted to avoid abandonment:

- A replacement abstract not exceeding 150 words in length and commencing on a separate sheet in compliance with 37 CFR 1.72(b) and 37 CFR 1.121 is required.
- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

Replies should be mailed to: Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

---

*A copy of this notice **MUST** be returned with the reply.*

Meazo-W  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE